Purpose of review This article realizes an overview on the world of biological and biosimilar drugs in allergic and immunologic diseases' treatment strategies. We started talking about the history of asthma treatment's progresses, continuing to daily biological therapies, concluding with the economic point of view. Recent findings Nowadays, the only pharmacological-biological approach approved for allergic diseases is omalizumab. Several other monoclonal antibodies are currently running premarketing studies but the costs of these therapies are difficult to be sustained by healthcare systems. Summary Several biological treatments have gone or are going off-patent, opening the drug market to biosimilars. In this way, in future, it will be possible to reduce health costs and increase accessibility to therapies that currently are not affordable to all patients.

Biosimilars in allergic diseases

FERRANDO, MATTEO;BAGNASCO, DIEGO;BRAIDO, FULVIO;CANONICA, GIORGIO
2016-01-01

Abstract

Purpose of review This article realizes an overview on the world of biological and biosimilar drugs in allergic and immunologic diseases' treatment strategies. We started talking about the history of asthma treatment's progresses, continuing to daily biological therapies, concluding with the economic point of view. Recent findings Nowadays, the only pharmacological-biological approach approved for allergic diseases is omalizumab. Several other monoclonal antibodies are currently running premarketing studies but the costs of these therapies are difficult to be sustained by healthcare systems. Summary Several biological treatments have gone or are going off-patent, opening the drug market to biosimilars. In this way, in future, it will be possible to reduce health costs and increase accessibility to therapies that currently are not affordable to all patients.
File in questo prodotto:
File Dimensione Formato  
Ferrando biosimilarsi in allergic diseases.pdf

accesso chiuso

Tipologia: Documento in versione editoriale
Dimensione 15.83 MB
Formato Adobe PDF
15.83 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Ferrando biosimilarsi in allergic diseases-compresso.pdf

accesso chiuso

Tipologia: Documento in versione editoriale
Dimensione 8.29 MB
Formato Adobe PDF
8.29 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11567/844298
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 10
social impact